An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies

Journal of Clinical Rheumatology

Volumn 21, Issue 3, 2015, Pages 115-119

  Bandrés Ciga, Sara ^a   Salvatierra, Juan ^b   López Sidro, Mar ^c   García Sánchez, Antonio ^c   Durán, Raquel ^a   Vives, Francisco ^a   Raya Álvarez, Enrique ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b Rheumatology Division   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

adalimumab; clinical failure; etanercept; immunogenicity; inflammatory arthropathies

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIBODY; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ANTIBODY BLOOD LEVEL; ARTHROPATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE DURATION; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; FOLLOW UP; IMMUNOGENETICS; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT FAILURE;

ADALIMUMAB; ADULT; AGED; ANTIBODIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGENETICS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84926640580     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000229     Document Type: Article

References (26)

1. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339-353.
2. Remy A, Avonac J, Gossec L, et al. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 2011;29:96-103.
3. Krieckaert CL, Bartelds GM, Lems WF, et al. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010;12:217.
4. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711-715.
5. Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1445-1452.
6. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009; 68:1739-1745.
7. Davis J, Peng JZ, Noertersheuser PA, et al. Pharmacokinetics of Adalimumab in patients with active ankylosing spondylitis (AS)-the Atlas trial [abstract]. Ann Rheum Dis. 2006;65(suppl II):537.
8. de Vries MK,Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis. 2007;66:1252-1254.
9. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with anti-adalimumab formation. Ann Rheum Dis. 2009;68:1787-1788.
10. Plasencia C, Pascual-Salcedo D, Nuño L, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in spondyloarthritis. Ann Rheum Dis. 2012;71:1955-1960.
11. van Kuijk AW, de Groot M, Stapel SO, et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69:624-625.
12. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340: 253-259.
13. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:40-46.
14. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial. Ann InternMed. 1999; 130:478-486.
15. Klareskog L, Wajdula J, Baker P, et al. Low and transient auto-and antietanercept antibody formation has no measurable impact on clinical outcomes during 5 years of etanercept (Enbrel) treatment in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis. 2006;65(suppl I):325.
16. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. Immunogenicity does not influence treatment with etanercept in patients with anlylosing spondylitis. Ann Rheum Dis. 2009;68:531-535.
17. Kosmač M, Avčin T, Toplak N, et al. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res. 2011;69:243-248.
18. van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72:104-109.
19. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:164-172.
20. Krieckaert C, Rispens T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24: 306-311.
21. Bartelds GM,Wijbrandts CA, NurmohamedMT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentration in rheumatoid arthritis. Ann Rheum Dis. 2007; 66:921-926.
22. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305:1460-1468.
23. Jamnitski A, Bartelds GM, Nurmohamed MT, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70:284-288.
24. Bartelds GM, Wijbrandts CA, NurmohamedMT, et al. Antiinfliximab and antiadalimumab antibodies in relation to response to adalimumab in infliximab switchers and antitumor necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69:817-821.
25. Lovell DJ, Ruperto N, Goodman S, et al. Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810-820.
26. Maini RN, Breedveld FC,Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.